(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 16.56% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.61%.
Pulmonx's revenue in 2024 is $76,583,000.On average, 2 Wall Street analysts forecast LUNG's revenue for 2024 to be $3,262,386,479, with the lowest LUNG revenue forecast at $3,257,492,410, and the highest LUNG revenue forecast at $3,267,280,548. On average, 2 Wall Street analysts forecast LUNG's revenue for 2025 to be $3,963,608,703, with the lowest LUNG revenue forecast at $3,921,911,234, and the highest LUNG revenue forecast at $4,005,306,172.
In 2026, LUNG is forecast to generate $4,764,356,717 in revenue, with the lowest revenue forecast at $4,638,559,564 and the highest revenue forecast at $4,890,153,870.